Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Dominari (NASDAQ:DOMH – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.
Profitability
This table compares Enlivex Therapeutics and Dominari’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
| Dominari | -31.37% | -206.20% | -155.26% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Enlivex Therapeutics and Dominari, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Enlivex Therapeutics and Dominari”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($8.25) | -0.57 |
| Dominari | $123.10 million | 0.52 | -$22.43 million | ($4.03) | -0.70 |
Enlivex Therapeutics has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Enlivex Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Summary
Enlivex Therapeutics beats Dominari on 9 of the 13 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
